Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View
by Zacks Equity Research
Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.
Intel, Edwards Lifesciences Top Q1 Earnings Estimates
by Mark Vickery
The chipmaker giant and the MedTech company both outperformed expectations in their Q1 earnings reports.
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 17.05% and 7.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform and TAVR treatments is likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Edwards Lifesciences (EW) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $217.52, moving +1.34% from the previous trading session.
Edwards Lifesciences (EW) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $5 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $194.73, marking a -0.35% move from the previous day.
Edwards Lifesciences, The Trade Desk, Blue Apron, Domino's Pizza and Grubhub highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Edwards Lifesciences, The Trade Desk, Blue Apron, Domino's Pizza and Grubhub highlighted as Zacks Bull and Bear of the Day
Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences
by Zacks Equity Research
Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences
Bull of the Day: Edwards Lifesciences (EW)
by Kevin Cook
While most elective procedures are being deferred, the innovator of minimally-invasive heart valve replacement beats on
5 Superstar Stocks on Sale During the Coronavirus Crisis
by Tracey Ryniec
Stocks are the only thing people won't buy when they go on sale. But with stocks in a bear market, now's your chance to pick up some of the best companies.
Medtronic Demonstrates All-Line Growth Despite Cost Concerns
by Zacks Equity Research
Major business lines of Medtronic (MDT) register stellar growth across all customer groups and geographies in Q3.
Here's Why You Should Buy Edwards Lifesciences Stock Now
by Zacks Equity Research
Investor confidence is high in Edwards Lifesciences (EW) stock, courtesy of solid prospects.
Why Is Edwards Lifesciences (EW) Down 12.5% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Edwards Lifesciences (EW) Stock Might be a Great Pick
by Zacks Equity Research
Edwards Lifesciences (EW) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More
by Urmimala Biswas
Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.
The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences
Coronavirus Starting to Weigh on 2020 Q1 Earnings Estimates
by Sheraz Mian
In addition to featuring fresh research reports on Exxon (XOM), Chevron (CVX), IBM (IBM) and others, today's Research Daily provides the Q4 earnings season update.
Edwards Lifesciences (EW) Q4 Earnings Lag, Sales Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.
Edwards Lifesciences (EW) Misses Q4 Earnings Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.35% and 1.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
5 Top Non-Tech Earnings Charts
by Tracey Ryniec
It's not all about technology or social media companies. These 5 companies are also in the earnings spotlight.
Medical Products' Jan 30 Earnings Roster: TMO, EW & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Why Edwards Lifesciences (EW) Could Beat Earnings Estimates Again
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More
by Urmimala Biswas
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.